Form 4: Pliant Therapeutics Director Gayle A. Crowell Reports Stock Option Grant

Director Gayle A. Crowell reports receiving a stock option grant from Pliant Therapeutics, Inc.

Summary

• On June 13, 2024, Gayle A. Crowell, a director of Pliant Therapeutics, Inc., received a stock option grant for 26,764 shares of common stock.
• The exercise price of the option is $13.06 per share.
• The options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date (June 13, 2025) or the next annual meeting of stockholders, contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. It's a neutral event in the normal course of business.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the biotech industry.
• The vesting schedule described is fairly typical, with quarterly or annual vesting tied to continued service.
• The size of the grant (26,764 shares) would need to be compared to grants made to directors at comparable companies to assess its relative value.

Key Dates